Allogene Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ALLO Nasdaq 2830 allogene.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Allogene Therapeutics, Inc.

Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia - Apr 21st, 2026 6:30 am
Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026 - Apr 20th, 2026 6:30 am
Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock - Apr 16th, 2026 2:01 pm
Allogene Therapeutics (ALLO) Is Down 13.0% After $175M Equity Raise On ALPHA3 MRD Data Release – Has The Bull Case Changed? - Apr 15th, 2026 3:04 pm
Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases - Apr 15th, 2026 6:30 am
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock - Apr 14th, 2026 7:50 pm
ALLO Rises on Strong MRD Clearance With Cema-Cel in ALPHA3 Study - Apr 14th, 2026 10:14 am
Company News for Apr 14, 2026 - Apr 14th, 2026 3:03 am
Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform - Apr 13th, 2026 2:30 pm
Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock - Apr 13th, 2026 2:01 pm
Allogene Therapeutics Touts Early ALPHA3 Win: cema-cel MRD Clearance 58% vs 17%, No CRS/ICANS - Apr 13th, 2026 8:36 am
Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics’ MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma - Apr 13th, 2026 6:00 am
Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL - Apr 13th, 2026 5:30 am
Why Do Analysts See 180%+ Upside for Allogene Therapeutics (ALLO)? - Apr 12th, 2026 3:49 pm
Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026 - Apr 10th, 2026 2:02 pm
Why Allogene Therapeutics (ALLO) Says Its Lead Cancer Program Is Still on Track in 2026 - Mar 29th, 2026 2:46 pm
Piper Sandler Analysts Bullish on Allogene Therapeutics (ALLO) Ahead of Key ALPHA3 Data Readout - Mar 20th, 2026 1:16 pm
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4 - Mar 13th, 2026 9:24 am
Allogene Therapeutics, Inc. Q4 2025 Earnings Call Summary - Mar 13th, 2026 6:30 am
Allogene Therapeutics Inc (ALLO) Q4 2025 Earnings Call Highlights: Financial Stability and ... - Mar 12th, 2026 9:03 pm